Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

This study is testing a type of immune cell therapy called NY-ESO-1 TCR-T cells — where a patient's own T-cells are engineered to recognize and attack cancer cells — in people with advanced soft tissue sarcoma that has a specific protein target. **You may be eligible if...** - You are between 18 and 70 years old with advanced or metastatic soft tissue sarcoma confirmed by biopsy - Your cancer has progressed after first-line treatment - Your tumor tissue tests positive for a protein called NY-ESO-1 by immunohistochemistry - You have a specific immune system protein type called HLA-A*02:01 - At least one tumor is measurable on imaging - Your general health score is 0–2 and expected survival is more than 3 months **You may NOT be eligible if...** - Your tumor does not express NY-ESO-1 - You do not have the required HLA type - Your blood counts or organ function do not meet minimum requirements - You have severe heart failure or low heart pumping function Talk to your doctor to see if this trial is right for you.